Since type 1 interferons have shown some initial efficacy in treating COVID-19 infection (Sallard et al., 2020), it is possible that the SARS-CoV-2 virus interaction with both receptor and soluble ACE2 interferes with type 1 interferon response, as low levels of type 1 interferons have been found in COVID-19 patients (Salman et al., 2021). This evidence concerns the gene ACE2 and COVID-19.